Aveo Eyes Role For Tivozanib In US Kidney Cancer Market, Against The Odds
Executive Summary
In the Phase III TIVO-3 study, tivozanib is associated with a trend toward adverse survival and trial has missing data issues.
You may also be interested in...
Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Pfizer Well-Placed To Lead First-Line Advanced RCC Market
Two successful Phase III studies of Inlyta in combination with two distinct immunotherapies, including its own, Merck KGaA-partnered Bavencio, puts Pfizer in a very strong position in the advanced kidney cancer market.
Novartis Terminates Development Of Aveo Antibody
Novartis has walked away from Aveo’s cachexia candidate after a turbulent week in the development of the antibody program, three years after paying $15m for development and commercialization rights.